[ad_1]
L ‘Aifa, The Italian pharmaceutical agency, “just gave the go-ahead” to the vaccine Pfizer / BioNTech, announced the Minister of Health Roberto Speranza after the authorization for emergency use by Ema at European level. Therefore, the schedule envisaged by the first has been confirmed. vaccinations “in all Italian regions” from December 27 RSA healthcare and elderly staff.
Vaccine, hope: now we have an extra weapon
“It’s still difficult, but now we have an extra weapon. Power“Speranza said after Aifa’s announcement, it arrived during the Agency’s press conference.
“With excitement I announce the approval of the marketing authorization of the Pfizer BioNTech messenger RNA vaccine”, Aifa general manager began Nicola Magrini. The vaccine has been authorized for the entire population “over 16 years of age”.
Magrini explained that “The Comirnaty vaccine is indicated for those over 16 years of age and has no contraindications.“. The director added that”Special precautions are not required”For specific categories such as the elderly, immunosuppressed or pregnant and lactating women.
CTS monitors adverse reactions to vaccines
The activity of monitoring of adverse reactions will remain standing and will be coordinated by the Scientific Technical Committee. “Specific studies will be conducted in selected populations such as dialysis patients and patients with RSAMagrini said. In recent days, some hoaxes (such as the alleged death of nurse Tiffany Dover) about the side effects of vaccines have appeared on the web.
In the first weeks of administration, added the director, there will be no reservation mechanism, but call. The system will change with the subsequent participation of family doctors.
In the coming weeks, Aifa will provide a series of answers to the most frequently asked questions about the Covid-19 vaccine. The president of Aifa, Giorgio Palù, said that it is important “Try to answer even those who have doubts. You have to give a message that reassures and reassures”.
One of the main doubts concerns the efficacy of the vaccines also on the British variant of the coronavirus, which has spread to different parts of Europe, including Italy.
